Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETVAX phase IIb traveler study in Finnish adults visiting West Africa
2016-002690-35Phase 2Completed
- Sponsor
- Scandinavian Biopharma
- Start
- Mar 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in Enterotoxigenic Escherichia coli diarrhea and traveler's diarrhea (TD) comparing ETVAX with Placebo (2 arms). Primary endpoint: Safety: number of vaccine-attributable events. Started Mar 2017; status: completed.
02
Drugs
ETVAX
03
Conditions
Enterotoxigenic Escherichia coli diarrheatraveler's diarrhea (TD)
Beyond the preview
Go deeper on 2016-002690-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002690-35.